ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build

Summary ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected to comprise nearly 60% of 2026 revenue. Cortrophin guidance was lowered by ~$30M, but H2 expectations remain intact, with Q4 growth hinging on gout salesforce productivity. Recent generic launches and operating leverage from rare-disease expansion support robust adjusted EBITDA guidance of $285M–$300M for 2026. Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More » Pgiam/iStock via Getty Images In Morgan Stanley’s fireside chat on September 14, ANI Pharmaceuticals’ ( ANIP ) CEO Nikhil Lalwani described their business as twofold: the generic business and the rare-disease one. The problem, as we also saw in the This article was written by High Alpha Professor 560 Followers Follow Dubai-based investor focused on building a resilient, income-generating portfolio with a long-term growth mindset. My approach is primarily long-only, blending dividend-paying equities, REITs, and other income strategies with selective growth opportunities. I believe in disciplined, fundamentals-driven investing, prioritizing capital preservation while compounding returns over time. Originally from India. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.